| Empagliflozin, a novel selective sodium glucose cotransporter‐2 (SGLT‐2) inhibitor: characterisation and comparison with other SGLT‐2 inhibitors R Grempler, L Thomas, M Eckhardt, F Himmelsbach, A Sauer, DE Sharp, ... Diabetes, Obesity and Metabolism 14 (1), 83-90, 2012 | 687 | 2012 |
| Localization of cyclooxygenase-1 and-2 in adult and fetal human kidney: implication for renal function M Komhoff, HJ Grone, T Klein, HW Seyberth, RM Nusing American Journal of Physiology-Renal Physiology 272 (4), F460-F468, 1997 | 518 | 1997 |
| Expression of cyclooxygenase 1 and cyclooxygenase 2 in human synovial tissue: differential elevation of cyclooxygenase 2 in inflammatory joint diseases I Siegle, T Klein, JT Backman, JG Saal, RM Nüsing, P Fritz Arthritis & Rheumatism: Official Journal of the American College of …, 1998 | 278 | 1998 |
| Glucose-independent improvement of vascular dysfunction in experimental sepsis by dipeptidyl-peptidase 4 inhibition S Kröller-Schön, M Knorr, M Hausding, M Oelze, A Schuff, R Schell, ... Cardiovascular research 96 (1), 140-149, 2012 | 223 | 2012 |
| DPP-4 inhibition on top of angiotensin receptor blockade offers a new therapeutic approach for diabetic nephropathy ML Alter, IM Ott, K Von Websky, O Tsuprykov, Y Sharkovska, ... Kidney and Blood Pressure Research 36 (1), 119-130, 2013 | 221 | 2013 |
| Selective inhibition of cyclooxygenase 2 T Klein, RM Nüsing, J Pfeilschifter, V Ullrich Biochemical pharmacology 48 (8), 1605-1610, 1994 | 201 | 1994 |
| The inhibitory potency and selectivity of arginine substrate site nitric-oxide synthase inhibitors is solely determined by their affinity toward the different isoenzymes R Boer, WR Ulrich, T Klein, B Mirau, S Haas, I Baur Molecular pharmacology 58 (5), 1026-1034, 2000 | 189 | 2000 |
| The DPP-4 inhibitor linagliptin counteracts stroke in the normal and diabetic mouse brain: a comparison with glimepiride V Darsalia, H Ortsäter, A Olverling, E Darlöf, P Wolbert, T Nyström, T Klein, ... Diabetes 62 (4), 1289-1296, 2013 | 170 | 2013 |
| Linagliptin improves insulin sensitivity and hepatic steatosis in diet-induced obesity M Kern, N Klöting, HG Niessen, L Thomas, D Stiller, M Mark, T Klein, ... Plos one 7 (6), e38744, 2012 | 144 | 2012 |
| Effects of DPP-4 inhibitors on the heart in a rat model of uremic cardiomyopathy L Chaykovska, K von Websky, J Rahnenführer, M Alter, S Heiden, ... PloS one 6 (11), e27861, 2011 | 136 | 2011 |
| The novel DPP-4 inhibitors linagliptin and BI 14361 reduce infarct size after myocardial ischemia/reperfusion in rats B Hocher, Y Sharkovska, M Mark, T Klein, T Pfab International journal of cardiology 167 (1), 87-93, 2013 | 131 | 2013 |
| Immunolocalization of the four prostaglandin E2 receptor proteins EP1, EP2, EP3, and EP4 in human kidney R Morath, T Klein, HW SEYBERTH, RM NÜSING Journal of the American Society of Nephrology 10 (9), 1851-1860, 1999 | 127 | 1999 |
| The DPP-4 inhibitor linagliptin restores β-cell function and survival in human isolated islets through GLP-1 stabilization P Shah, A Ardestani, G Dharmadhikari, S Laue, DM Schumann, ... The Journal of Clinical Endocrinology & Metabolism 98 (7), E1163-E1172, 2013 | 124 | 2013 |
| The dipeptidyl peptidase-4 inhibitor linagliptin attenuates inflammation and accelerates epithelialization in wounds of diabetic ob/ob mice C Schürmann, A Linke, K Engelmann-Pilger, C Steinmetz, M Mark, ... Journal of Pharmacology and Experimental Therapeutics 342 (1), 71-80, 2012 | 123 | 2012 |
| Localization of cyclooxygenase-2 and prostaglandin E2 receptor EP3 in the rat lumbar spinal cord F Beiche, T Klein, R Nüsing, W Neuhuber, M Goppelt-Struebe Journal of neuroimmunology 89 (1-2), 26-34, 1998 | 118 | 1998 |
| Linagliptin alleviates hepatic steatosis and inflammation in a mouse model of non-alcoholic steatohepatitis T Klein, M Fujii, J Sandel, Y Shibazaki, K Wakamatsu, M Mark, ... Medical Molecular Morphology 47, 137-149, 2014 | 114 | 2014 |
| 15-hydroxyeicosatetraenoic acid is a preferential peroxisome proliferator-activated receptor β/δ agonist S Naruhn, W Meissner, T Adhikary, K Kaddatz, T Klein, B Watzer, ... Molecular pharmacology 77 (2), 171-184, 2010 | 114 | 2010 |
| The SGLT2 inhibitor empagliflozin improves insulin sensitivity in db/db mice both as monotherapy and in combination with linagliptin M Kern, N Klöting, M Mark, E Mayoux, T Klein, M Blüher Metabolism 65 (2), 114-123, 2016 | 109 | 2016 |
| Blood pressure and glucose independent renoprotective effects of dipeptidyl peptidase-4 inhibition in a mouse model of type-2 diabetic nephropathy Y Sharkovska, C Reichetzeder, M Alter, O Tsuprykov, S Bachmann, ... Journal of hypertension 32 (11), 2211-2223, 2014 | 108 | 2014 |
| Generation of the isoprostane 8-epi-prostaglandin F2α in vitro and in vivo via the cyclooxygenases T Klein, F Reutter, H Schweer, HW Seyberth, RM Nüsing Journal of Pharmacology and Experimental Therapeutics 282 (3), 1658-1665, 1997 | 105 | 1997 |
